Clinical Focus ›› 2021, Vol. 36 ›› Issue (7): 623-627.doi: 10.3969/j.issn.1004-583X.2021.07.010
Previous Articles Next Articles
Received:
2021-05-28
Online:
2021-07-20
Published:
2021-08-02
Contact:
Ma Bing
E-mail:malishuqing@sina.com
CLC Number:
Zhang Lihong, Ma Bing. Correlation between serum β-CTx and TRACP-5b and the severity and prognosis of multiple myeloma bone disease[J]. Clinical Focus, 2021, 36(7): 623-627.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.07.010
组别 | 例数 | β-CTx(μg/L) | TRACP-5b(ng/ml) |
---|---|---|---|
1级组 | 19 | 0.44±0.06 | 30.18±6.12 |
2级组 | 28 | 0.53±0.09* | 34.56±6.89* |
3级组 | 43 | 0.59±0.11*# | 38.07±7.23*# |
4级组 | 52 | 0.76±0.10*#△ | 42.51±8.42*#△ |
F值 | 48.799 | 15.107 | |
P值 | <0.01 | <0.01 |
组别 | 例数 | β-CTx(μg/L) | TRACP-5b(ng/ml) |
---|---|---|---|
1级组 | 19 | 0.44±0.06 | 30.18±6.12 |
2级组 | 28 | 0.53±0.09* | 34.56±6.89* |
3级组 | 43 | 0.59±0.11*# | 38.07±7.23*# |
4级组 | 52 | 0.76±0.10*#△ | 42.51±8.42*#△ |
F值 | 48.799 | 15.107 | |
P值 | <0.01 | <0.01 |
因素 | 生存组 (n=98) | 死亡组 (n=44) | 统计值 | P值 |
---|---|---|---|---|
男性[例(%)] | 61(62.24) | 30(68.18) | χ2=0.465 | 0.495 |
年龄(岁) | 57.36±5.82 | 59.24±6.73 | t=1.694 | 0.092 |
BMI(kg/m2) | 23.41±2.24 | 22.89±1.27 | t=1.438 | 0.153 |
恶性肿瘤家族史[例(%)] | 10(10.20) | 5(11.36) | χ2=0.043 | 0.835 |
免疫球蛋白分型[例(%)] | ||||
IgG型 | 58(59.18) | 28(63.64) | ||
IgA型 | 21(21.43) | 6(13.64) | χ2=1.240 | 0.872 |
IgD型 | 4(4.08) | 2(4.55) | ||
其他类型 | 15(15.31) | 8(18.18) | ||
ISS分期[例(%)] | ||||
Ⅰ期 | 31(31.63) | 9(20.45) | ||
Ⅱ期 | 43(43.88) | 14(31.82) | χ2=7.621 | 0.022 |
Ⅲ期 | 24(24.49) | 21(47.73) | ||
MMBD严重程度[例(%)] | ||||
1级 | 17(17.35) | 2(4.55) | ||
2级 | 24(25.51) | 4(9.10) | χ2=11.942 | 0.018 |
3级 | 28(28.57) | 15(34.10) | ||
4级 | 29(29.59) | 23(52.27) | ||
骨转移部位[例(%)] | ||||
脊柱 | 52(53.06) | 26(59.09) | ||
肋骨 | 29(29.59) | 12(27.27) | χ2=0.516 | 0.773 |
其他 | 17(17.35) | 6(13.64) | ||
溶骨性病变数量(≥2个) [例(%)] | 56(57.14) | 31(70.45) | χ2=2.268 | 0.132 |
骨病类型[例(%)] | ||||
骨质疏松 | 26(26.53) | 7(15.91) | ||
溶骨性破坏 | 39(39.80) | 16(36.36) | χ2=12.871 | 0.012 |
病理性骨折 | 15(15.31) | 18(40.91) | ||
其他 | 18(18.37) | 3(6.82) | ||
化疗方案[例(%)] | ||||
硼替佐米+环磷酰胺+ 地塞米松 | 39(39.80) | 17(38.64) | ||
硼替佐米+表柔比星+ 地塞米松 | 33(33.67) | 12(27.27) | χ2=1.004 | 0.605 |
长春新碱+表柔比星+ 地塞米松 | 26(26.53) | 15(34.09) | ||
血肌酐(μmol/L) | 164.56±12.97 | 168.61±13.45 | t=1.701 | 0.091 |
β2-MG(mg/L) | 4.95±0.78 | 5.73±1.21 | t=4.605 | <0.001 |
β-CTx(μg/L) | 0.56±0.08 | 0.78±0.13 | t=12.357 | <0.001 |
TRACP-5b(ng/ml) | 30.49±7.25 | 38.26±8.74 | t=5.533 | <0.001 |
因素 | 生存组 (n=98) | 死亡组 (n=44) | 统计值 | P值 |
---|---|---|---|---|
男性[例(%)] | 61(62.24) | 30(68.18) | χ2=0.465 | 0.495 |
年龄(岁) | 57.36±5.82 | 59.24±6.73 | t=1.694 | 0.092 |
BMI(kg/m2) | 23.41±2.24 | 22.89±1.27 | t=1.438 | 0.153 |
恶性肿瘤家族史[例(%)] | 10(10.20) | 5(11.36) | χ2=0.043 | 0.835 |
免疫球蛋白分型[例(%)] | ||||
IgG型 | 58(59.18) | 28(63.64) | ||
IgA型 | 21(21.43) | 6(13.64) | χ2=1.240 | 0.872 |
IgD型 | 4(4.08) | 2(4.55) | ||
其他类型 | 15(15.31) | 8(18.18) | ||
ISS分期[例(%)] | ||||
Ⅰ期 | 31(31.63) | 9(20.45) | ||
Ⅱ期 | 43(43.88) | 14(31.82) | χ2=7.621 | 0.022 |
Ⅲ期 | 24(24.49) | 21(47.73) | ||
MMBD严重程度[例(%)] | ||||
1级 | 17(17.35) | 2(4.55) | ||
2级 | 24(25.51) | 4(9.10) | χ2=11.942 | 0.018 |
3级 | 28(28.57) | 15(34.10) | ||
4级 | 29(29.59) | 23(52.27) | ||
骨转移部位[例(%)] | ||||
脊柱 | 52(53.06) | 26(59.09) | ||
肋骨 | 29(29.59) | 12(27.27) | χ2=0.516 | 0.773 |
其他 | 17(17.35) | 6(13.64) | ||
溶骨性病变数量(≥2个) [例(%)] | 56(57.14) | 31(70.45) | χ2=2.268 | 0.132 |
骨病类型[例(%)] | ||||
骨质疏松 | 26(26.53) | 7(15.91) | ||
溶骨性破坏 | 39(39.80) | 16(36.36) | χ2=12.871 | 0.012 |
病理性骨折 | 15(15.31) | 18(40.91) | ||
其他 | 18(18.37) | 3(6.82) | ||
化疗方案[例(%)] | ||||
硼替佐米+环磷酰胺+ 地塞米松 | 39(39.80) | 17(38.64) | ||
硼替佐米+表柔比星+ 地塞米松 | 33(33.67) | 12(27.27) | χ2=1.004 | 0.605 |
长春新碱+表柔比星+ 地塞米松 | 26(26.53) | 15(34.09) | ||
血肌酐(μmol/L) | 164.56±12.97 | 168.61±13.45 | t=1.701 | 0.091 |
β2-MG(mg/L) | 4.95±0.78 | 5.73±1.21 | t=4.605 | <0.001 |
β-CTx(μg/L) | 0.56±0.08 | 0.78±0.13 | t=12.357 | <0.001 |
TRACP-5b(ng/ml) | 30.49±7.25 | 38.26±8.74 | t=5.533 | <0.001 |
自变量 | 回归 系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
骨病类型(病理性 骨折) | 1.207 | 0.268 | 18.886 | 0.000 | 3.243 | 1.846 | 5.927 |
β-CTx | 1.152 | 0.281 | 15.070 | 0.000 | 3.065 | 1.602 | 5.243 |
MMBD严重程度 (4级) | 1.041 | 0.294 | 11.065 | 0.000 | 2.932 | 1.539 | 4.926 |
ISS分期(Ⅲ期) | 1.006 | 0.305 | 7.789 | 0.001 | 2.635 | 1.447 | 4.335 |
TRACP-5b | 0.691 | 0.317 | 5.133 | 0.018 | 1.996 | 1.216 | 4.058 |
β2-MG | 0.604 | 0.326 | 3.433 | 0.037 | 1.829 | 1.037 | 3.129 |
自变量 | 回归 系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
骨病类型(病理性 骨折) | 1.207 | 0.268 | 18.886 | 0.000 | 3.243 | 1.846 | 5.927 |
β-CTx | 1.152 | 0.281 | 15.070 | 0.000 | 3.065 | 1.602 | 5.243 |
MMBD严重程度 (4级) | 1.041 | 0.294 | 11.065 | 0.000 | 2.932 | 1.539 | 4.926 |
ISS分期(Ⅲ期) | 1.006 | 0.305 | 7.789 | 0.001 | 2.635 | 1.447 | 4.335 |
TRACP-5b | 0.691 | 0.317 | 5.133 | 0.018 | 1.996 | 1.216 | 4.058 |
β2-MG | 0.604 | 0.326 | 3.433 | 0.037 | 1.829 | 1.037 | 3.129 |
[1] | 欧阳清, 刘健, 石青峰, 等. β-CTx, T-PINP检测在评估骨髓瘤骨病的临床价值[J]. 检验医学与临床, 2017,18(14):95-96. |
[2] |
Joshua DE, Bryant C, Dix C, et al. Biology and therapy of multiple myeloma[J]. Med J Aust, 2019,210(8):375-380.
doi: 10.5694/mja2.v210.8 URL |
[3] |
Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Pathogenesis of bone disease in multiple myeloma: from bench to bedside[J]. Blood Cancer J, 2018,8(1):7.
doi: 10.1038/s41408-017-0037-4 URL |
[4] | 刘巍峰, 王涛, 李远, 等. 多发性骨髓瘤骨病的外科治疗及预后因素[J]. 中华骨科杂志, 2018,38(14):841-850. |
[5] | 朱丽英, 胡春艳, 贠春燕, 等. 血清Ⅰ型前胶原氨基端前肽与Ⅰ型胶原羧基端肽β特殊序列在恶性肿瘤骨转移诊断和病情评估及疗效评价中的应用价值[J]. 中医正骨, 2018,30(6):36-39. |
[6] | 马荣军, 杨世伟, 袁晓莉, 等. 蛋白酶体抑制剂对骨髓瘤骨病患者血清骨代谢物的影响及临床意义[J]. 中华医学杂志, 2020,100(26):2032-2035. |
[7] | 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2015年修订)[J]. 中华内科杂志, 2015,54(12):1066-1069. |
[8] | 中华医学会血液学分会. 多发性骨髓瘤骨病诊治指南[J]. 中华血液学杂志, 2011,32(10):721-723. |
[9] |
Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma[J]. J Clin Oncol, 2005,23(15):3412-3420.
doi: 10.1200/JCO.2005.04.242 URL |
[10] | 杨世伟, 马荣军, 赵娟娟, 等. 血清β-CTx/PINP在多发性骨髓瘤骨病及骨转移瘤中的临床意义[J]. 中华医学杂志, 2018,98(32):2583-2587. |
[11] |
Crevenna R. Typical aspects in the rehabilitation of cancer patients suffering from metastatic bone disease or multiple myeloma[J]. Wien Klin Wochenschr, 2019,131(21):567-575.
doi: 10.1007/s00508-019-1524-3 URL |
[12] |
Raeve H, Schots R, Vanderkerken K, et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts[J]. Blood Cancer J, 2018,8(11):105.
doi: 10.1038/s41408-018-0139-7 URL |
[13] |
Auzina D, Erts R, Lejniece S. Prognostic value of the bone turnover markers in multiple myeloma[J]. Exp Oncol, 2017,39(1):53-56.
pmid: 28361850 |
[14] |
Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease[J]. Clin Chem, 2017,63(2):464-474.
doi: 10.1373/clinchem.2016.259085 pmid: 27940448 |
[15] |
Vallet S, Hoyle NR, Kyle RA, et al. A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma[J]. Leuk Lymphoma, 2018,59(10):2431-2438.
doi: 10.1080/10428194.2017.1421757 URL |
[16] | 翟云芝, 张浩然. 骨代谢标志物在多发性骨髓瘤中的临床应用[J]. 蚌埠医学院学报, 2018, 43(9):20-21+25. |
[17] |
Mira-Pascual L, Patlaka C, Desai S, et al. A novel sandwich ELISA for tartrate-resistant acid phosphatase 5a and 5b protein reveals that both isoforms are secreted by differentiating osteoclasts and correlate to the type I collagen degradation marker CTX-I in vivo and in vitro[J]. Calcif Tissue Int, 2020,106(2):194-207.
doi: 10.1007/s00223-019-00618-w URL |
[18] | Zhang Q, Cao L, Miao XD, et al. Diagnostic value of TRACP5b expression in patients with bone tumors[J]. J Biol Regul Homeost Agents, 2019,33(2):557-562. |
[19] | 褚彬, 陆敏秋, 吴梦青, 等. 多发性骨髓瘤骨病临床特点及监测骨代谢标志物的临床意义[J]. 中华医学杂志, 2016,96(18):1424-1429. |
[20] | 许京淑, 向航, 邹禄平, 等. PCD方案治疗伴或不伴有骨病的多发性骨髓瘤疗效和预后比较及其与血清相关检测指标的相关性[J]. 现代肿瘤医学, 2020,28(18):3231-3235. |
[21] | 陆敏秋, 项秋晴, 褚彬, 等. 多发性骨髓瘤预后的影响因素研究[J]. 中国全科医学, 2016,19(6):658-665. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||